JP2010524435A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010524435A5 JP2010524435A5 JP2010501433A JP2010501433A JP2010524435A5 JP 2010524435 A5 JP2010524435 A5 JP 2010524435A5 JP 2010501433 A JP2010501433 A JP 2010501433A JP 2010501433 A JP2010501433 A JP 2010501433A JP 2010524435 A5 JP2010524435 A5 JP 2010524435A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr
- set forth
- region
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 21
- 229920001184 polypeptide Polymers 0.000 claims 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 241000282577 Pan troglodytes Species 0.000 claims 1
- 241000288959 Saguinus Species 0.000 claims 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 1
- 230000009831 antigen interaction Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07006988 | 2007-04-03 | ||
| EP07006990 | 2007-04-03 | ||
| US91366807P | 2007-04-24 | 2007-04-24 | |
| EP07020646 | 2007-10-22 | ||
| EP07020640 | 2007-10-22 | ||
| EP07020641 | 2007-10-22 | ||
| EP08004741 | 2008-03-13 | ||
| PCT/EP2008/002663 WO2008119566A2 (en) | 2007-04-03 | 2008-04-03 | Cross-species-specific bispecific binders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013218769A Division JP6016747B2 (ja) | 2007-04-03 | 2013-10-22 | 種間特異的二重特異性バインダー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010524435A JP2010524435A (ja) | 2010-07-22 |
| JP2010524435A5 true JP2010524435A5 (OSRAM) | 2011-05-19 |
Family
ID=42582614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501433A Revoked JP2010524435A (ja) | 2007-04-03 | 2008-04-03 | 種間特異的二重特異性バインダー |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JP2010524435A (OSRAM) |
| DK (1) | DK2155788T3 (OSRAM) |
| ES (1) | ES2390243T3 (OSRAM) |
| NZ (1) | NZ580746A (OSRAM) |
| PT (1) | PT2155788E (OSRAM) |
| RS (1) | RS52492B (OSRAM) |
| RU (1) | RU2535992C2 (OSRAM) |
| SI (1) | SI2155788T1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008234019B2 (en) * | 2007-04-03 | 2014-05-29 | Amgen Research (Munich) Gmbh | Cross-species-specific bispecific binders |
| KR101589759B1 (ko) * | 2007-04-03 | 2016-01-29 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 ｃｄ３―입실론 결합 도메인 |
| EP2640750A1 (en) * | 2010-11-16 | 2013-09-25 | Boehringer Ingelheim International GmbH | Agents and methods for treating diseases that correlate with bcma expression |
| EP2710042A2 (en) * | 2011-05-16 | 2014-03-26 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| ME03440B (me) * | 2011-05-21 | 2020-01-20 | Macrogenics Inc | Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3 |
| KR102357961B1 (ko) | 2013-12-17 | 2022-02-08 | 제넨테크, 인크. | 항-cd3 항체 및 이의 사용 방법 |
| RU2016151235A (ru) * | 2014-05-28 | 2018-06-28 | Ф. Хоффманн-Ля Рош Аг | Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус |
| WO2016014974A2 (en) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| AR101400A1 (es) * | 2014-07-31 | 2016-12-14 | Amgen Res Munich Gmbh | Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido |
| HK1250997A1 (zh) * | 2015-05-01 | 2019-01-18 | 基因泰克公司 | 掩蔽抗cd3抗体和使用方法 |
| JP7034489B2 (ja) | 2016-03-15 | 2022-03-14 | アイタブメッド （エイチケイ） リミテッド | 多重特異性Ｆａｂ融合タンパクおよびその使用 |
| WO2018093821A1 (en) | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| US10426424B2 (en) | 2017-11-21 | 2019-10-01 | General Electric Company | System and method for generating and performing imaging protocol simulations |
| MX2020008289A (es) | 2018-02-08 | 2020-09-25 | Genentech Inc | Moleculas biespecificas de union al antigeno y metodos de uso. |
| EP3847196A4 (en) | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
| US20230067182A1 (en) * | 2019-11-29 | 2023-03-02 | Boe Technology Group Co., Ltd. | Data Processing Device and Method, and Computer Readable Storage Medium |
| BR112022011357A2 (pt) | 2019-12-13 | 2022-08-23 | Genentech Inc | Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo |
| JP2022087602A (ja) * | 2020-12-01 | 2022-06-13 | 株式会社バイオピーク | 組換え大腸菌による有用タンパク質の生産性を向上するための培養方法 |
| US12291575B2 (en) | 2021-05-14 | 2025-05-06 | Genentech, Inc. | Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| CN115932808B (zh) * | 2022-11-04 | 2025-05-27 | 四川九洲电器集团有限责任公司 | 一种基于多特征融合的被动声纳智能探测方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2179862C1 (ru) * | 2000-12-26 | 2002-02-27 | Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" | Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки |
| KR20060015602A (ko) * | 2003-05-31 | 2006-02-17 | 마이크로메트 에이지 | ＥｐＣＡＭ 에 대한 이중 특이성 항체를 포함하는약학조성물 |
| US7235641B2 (en) * | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| ES2526343T3 (es) * | 2004-06-03 | 2015-01-09 | Novimmune Sa | Anticuerpos anti-CD3 y métodos de uso de los mismos |
| US20100209437A1 (en) * | 2005-09-12 | 2010-08-19 | Greg Elson | Anti-CD3 Antibody Fromulations |
| ES2856451T3 (es) * | 2005-10-11 | 2021-09-27 | Amgen Res Munich Gmbh | Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas |
-
2008
- 2008-04-03 SI SI200830762T patent/SI2155788T1/sl unknown
- 2008-04-03 RU RU2009136913/10A patent/RU2535992C2/ru active
- 2008-04-03 RS RS20120412A patent/RS52492B/sr unknown
- 2008-04-03 PT PT08735000T patent/PT2155788E/pt unknown
- 2008-04-03 DK DK08735000.5T patent/DK2155788T3/da active
- 2008-04-03 ES ES08735000T patent/ES2390243T3/es active Active
- 2008-04-03 NZ NZ580746A patent/NZ580746A/en unknown
- 2008-04-03 JP JP2010501433A patent/JP2010524435A/ja not_active Revoked
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010524435A5 (OSRAM) | ||
| HRP20120759T1 (hr) | Bispecifična veziva specifična između vrsta | |
| FI2155783T4 (fi) | Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni | |
| TWI769537B (zh) | 標靶ｂｃｍａ的抗體、雙專一性抗體及其用途 | |
| JP2019501883A5 (OSRAM) | ||
| JP2020062036A5 (OSRAM) | ||
| JP2022061992A5 (OSRAM) | ||
| HRP20190932T1 (hr) | Molekule protutijela koje se vežu na il-17a i il-17f | |
| JP2017522892A5 (OSRAM) | ||
| CN115003333A (zh) | Pvrig结合蛋白及其医药用途 | |
| JP2013528569A5 (OSRAM) | ||
| JP2013056885A5 (OSRAM) | ||
| ME02581B (me) | Farmaceutski pripravci s otpornošću na topljivi cea | |
| JP2015504306A5 (OSRAM) | ||
| HRP20130883T4 (hr) | Međuvrsno specifična cd3-epsilon-vežuća domena | |
| JP2018526981A5 (OSRAM) | ||
| JP2014534242A5 (OSRAM) | ||
| JP2018521638A5 (OSRAM) | ||
| RU2019128134A (ru) | Антитело против gprc5d и молекула, содержащая антитело | |
| JP2016511277A5 (OSRAM) | ||
| JP2016512551A5 (OSRAM) | ||
| HRP20110187T1 (hr) | Multispecifične deimunizirane tvari koje vežu cd3 | |
| RU2009136913A (ru) | Биспецифические связывающие агенты с межвидовой специфичностью | |
| JP2012504403A5 (OSRAM) | ||
| JP2016511750A5 (OSRAM) |